Turnstone Biologics 5/12/2025 Earnings Report

Turnstone Biologics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.26
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Turnstone Biologics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Turnstone Biologics Announcement Details

• Date: 5/12/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Turnstone Biologics (NASDAQ:TSBX), a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.